Strong FY25 growth tempered by the Q4 miss
26/02/26 -"Novonesis stumbled at the finish line — Q4 25 revenue and EBITDA missed consensus by 2.3% and 2.9% respectively, dragged down by weakness in the Planetary Health division. Margins held up well, with ..."
Pages
51
Language
English
Published on
26/02/26
You may also be interested by these reports :
26/02/26
Even though the H2 25 results were ahead of consensus, the 2026 outlook was below the street’s expectations. While Branded posted strong H2 growth, ...
26/02/26
Novonesis stumbled at the finish line — Q4 25 revenue and EBITDA missed consensus by 2.3% and 2.9% respectively, dragged down by weakness in the ...
26/02/26
The H2 25 results exceeded the consensus, and the 2026 guidance (CER) was better than the consensus estimates at AER. The H2 performance was driven ...
25/02/26
While Q4 sales met the street’s expectations, H2 25 profitability somewhat exceeded the consensus. Most of the Q4 growth was driven by strong demand ...